Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Profit After Tax (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed Profit After Tax for 4 consecutive years, with -$21.1 million as the latest value for Q4 2025.

  • Quarterly Profit After Tax rose 71.59% to -$21.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$221.2 million through Dec 2025, up 33.82% year-over-year, with the annual reading at -$221.2 million for FY2025, 33.82% up from the prior year.
  • Profit After Tax for Q4 2025 was -$21.1 million at Phathom Pharmaceuticals, up from -$30.0 million in the prior quarter.
  • The five-year high for Profit After Tax was -$21.1 million in Q4 2025, with the low at -$94.3 million in Q1 2025.
  • Average Profit After Tax over 4 years is -$59.7 million, with a median of -$53.1 million recorded in 2022.
  • The sharpest move saw Profit After Tax tumbled 123.23% in 2024, then skyrocketed 71.59% in 2025.
  • Over 4 years, Profit After Tax stood at -$55.0 million in 2022, then crashed by 44.55% to -$79.6 million in 2023, then grew by 6.43% to -$74.5 million in 2024, then surged by 71.59% to -$21.1 million in 2025.
  • According to Business Quant data, Profit After Tax over the past three periods came in at -$21.1 million, -$30.0 million, and -$75.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.